<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: This study sought to prospectively determine the frequency of delayed <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo> with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy following day 1 prophylaxis with a <z:chebi fb="0" ids="28790">5-HT</z:chebi>-(3) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Patients with <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, ≥ age 18, with a performance status ≤ 2, receiving <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (85-100 mg/m(2)) as part of a standard folinic acid, <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> regimen for the first time were eligible </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received a <z:chebi fb="0" ids="28790">5-HT</z:chebi>(3) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> 20 mg on day 1 prior to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>No routine prophylaxis for delayed <z:hpo ids='HP_0002013'>emesis</z:hpo> was given </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="50919">Antiemetic</z:chebi> outcome was recorded in patient-completed diaries for the 120-h study period following <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> administration </plain></SENT>
<SENT sid="5" pm="."><plain>Primary endpoint was frequency of delayed (24-120 h) <z:hpo ids='HP_0002013'>emesis</z:hpo> (<z:hpo ids='HP_0002013'>vomiting</z:hpo>/retching) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Forty-one patients were enrolled and 39 are evaluable </plain></SENT>
<SENT sid="7" pm="."><plain>Median age was 70 (34-85) and the female/male ratio was 20:19 </plain></SENT>
<SENT sid="8" pm="."><plain>Four patients (10%) experienced <z:hpo ids='HP_0002013'>vomiting</z:hpo> or retching during the delayed period </plain></SENT>
<SENT sid="9" pm="."><plain>One patient vomited during the first 24 h after <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>The overall (120 h) no <z:hpo ids='HP_0002013'>emesis</z:hpo> rate was 87% (34/39) </plain></SENT>
<SENT sid="11" pm="."><plain>Twenty-one patients (54%) developed delayed <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Nine patients had moderate or severe <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Eighteen patients (46%) took rescue <z:chebi fb="0" ids="50919">antiemetics</z:chebi> during the delayed period </plain></SENT>
<SENT sid="14" pm="."><plain>Delayed and overall complete response (no <z:hpo ids='HP_0002013'>emesis</z:hpo> or use of rescue <z:chebi fb="0" ids="50919">antiemetics</z:chebi>) rates were 54% and 49%, respectively </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: The use of a <z:chebi fb="0" ids="28790">5-HT</z:chebi>(3) <z:chebi fb="68" ids="48706">antagonist</z:chebi> and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> prior to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> results in excellent control of <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo> (CR-90%) during the 24 h after chemotherapy </plain></SENT>
<SENT sid="16" pm="."><plain>However, without further <z:chebi fb="0" ids="50919">antiemetic</z:chebi> treatment, complete response in the delayed period decreased to 54% </plain></SENT>
<SENT sid="17" pm="."><plain>This study supports the need for routine <z:chebi fb="0" ids="50919">antiemetic</z:chebi> prophylaxis for delayed <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo> following <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy </plain></SENT>
</text></document>